Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carmustine + diaziquone
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Combination of two alkylating agents used in the treatment of brain tumors, particularly anaplastic gliomas. Both drugs interfere with cancer cell growth by disrupting DNA replication. The combination has shown enhanced therapeutic effects in preclinical studies compared to either agent alone, particularly in human glioma and medulloblastoma tumor lines.
- Brand names
- BiCNU + AZQ
- Other names
- N,N'-Bis(2-chloroethyl)-N-nitrosourea + diaziquonebis-chloroethylnitrosourea + diaziquone
02
Targets
GSR (Glutathione reductase)DNA
Beyond the preview
Go deeper on carmustine + diaziquone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carmustine + diaziquone.